• NIFTY  
    11,521.05
    (-0.10%)
  • SENSEX  
    38,386.75
    ( 0.06%)
  • USDINR  
    68.96
    ( 0.62%)
  • GOLD  
    31,830.00
    ( 0.42%)
  • Hot Pursuit - Detailed News

Glenmark Pharma gains after USFDA approval
15-Mar-19   11:07 Hrs IST
The announcement was made during trading hours today, 15 March 2019.

Meanwhile, the S&P BSE Sensex was up 245.07 points, or 0.65% to 37,999.96.

On the BSE, 26,000 shares were traded in the counter so far compared with average daily volumes of 1.51 lakh shares in the past two weeks. The stock had hit a high of Rs 651.50 and a low of Rs 634.80 so far during the day. The stock hit a 52-week high of Rs 711.55 on 10 September 2018. The stock hit a 52-week low of Rs 483.60 on 30 May 2018.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for clindamycin and benzoyl peroxide gel, 1% / 5%, a generic version of BenzaClin Gel, 1% / 5%, of Valeant Bermuda.

According to IQVIA sales data for the 12 month period ending January 2019, the BenzaClin Gel, 1% / 5% market achieved annual sales of approximately $99.4 million.

Glenmark's current portfolio consists of 151 products authorized for distribution in the US marketplace and 53 ANDA's pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

On a consolidated basis, Glenmark Pharmaceuticals' net profit rose 11.08% to Rs 116.34 crore on 15.58% increase in net sales to Rs 2509.78 crore in Q3 December 2018 over Q3 December 2017.

Glenmark Pharmaceuticals (GPL) is a research-driven, global, integrated pharmaceutical organisation.

Powered by Capital Market - Live News

Useful Links

Attention Investors
Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day.............issued in the interest of investors. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account                                    "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
Investors should be cautious of unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.BSE   http://www.bseindia.com/investors/tip-off-registration.aspx?expandable  NSE   https://www.nseindia.com/int_invest/dynacontent/any_portal.htm
All payments to Stock Broker shall be received from the market intermediaries/participants strictly by account payee crossed cheques / demand drafts or by way of direct credit into the bank account through electronic fund transfer, or any other mode permitted by the Reserve Bank of India. Stock Brokers shall not accept cash from their clients either directly or by way of cash deposit to the Bank Account of Stock Broker.
Group Companies Members of : BSE, NSE, MCX, MCX.SX, CDSL, NCDEX, Broking Services, Depository Services, Portfolio Management Services, Member Area IPO Distribution, Insurance Broking
BSE Clearing No.: 911 | SEBI Regn. No.: INZ000177531 (Cash/F&O) | NSE Clearing No.: 11858 | SEBI Regn. No. INZ000177531 (Cash/F&O/CDs) | MCX-SX Clearing No.: 11400 | SEBI Regn. No.: INZ000177531 (CDs) | CDSL DP ID: 30300 | SEBI Regn. No.: IN-DPCDSL-210-2003 | MCX SEBI Reg No.: INZ000032336 | MCX: 10665 | NCDEX: 00254 | NBFC RBI Regn. No.: 13.01851
© Copyright 2018 Ajmera Associates Ltd ( ISO 9001:2015 Certified )
Designed, Developed and Powered By CMOTS Infotech ( ISO 9001:2015 Certified )